Julia Rotow, MD

This segment interprets PHAROS results in a real-world clinical context, emphasizing that despite excellent frontline activity, long-term survival remains limited by complex resistance patterns and post-progression challenges.

This segment reviews the strong efficacy findings from PHAROS—particularly the ~30-month median PFS in frontline patients—positioning the regimen as a major advancement in BRAF-mutant NSCLC therapy.

This segment introduces the PHAROS trial design and rationale, describing how its dual-cohort structure and long follow-up provide foundational evidence for encorafenib + binimetinib in this rare population.

This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.